Pancreatic Cancer Research

Stephen J. Pandol, MD


Cedars-Sinai Medical Center








- Overview of anatomy and function of the pancreas.
- Nature of pancreatic cancer
- Inter-relationship between pancreatic disorders
- How we study pancreatic cancer and develop treatments and early diagnosis methods
- The road to defeating this disease


































Inter-relationship between pancreatic disorders















Inter-relationship between pancreatic disorders



How we study pancreatic cancer and develop treatments and early diagnosis methods

Human studies

Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreatic Cancer Clinical Centers (CSCPDPC CCs) Research Objectives

Identify and acquire cohorts of well characterized patients and associated bio-specimens (blood, pancreatic and duodenal juice, stools and when feasible pancreatic tissue) to pursue clinical research in types of patients shown in the following slide.

- (1) Patients with pancreatitis to encourage translational research focusing upon elucidating the pathogenesis that will provide the basis for understanding the natural history and developing means of diagnosis, treatment and clinical management and its sequelae: chronic pain, pancreatic insufficiency, diabetes and pancreatic cancer.
- (2) Patients with pancreatic cancer and pancreatogenic Diabetes Mellitus (T3cDM) to encourage translational research focusing on their mechanistic inter-relationships in order to develop better means for prevention, diagnosis, and treatment of these disorders.

The Pancreatic Cancer Detection Consortium (U01)


This Funding Opportunity Announcement (FOA) invites applications from multi-disciplinary teams of researchers and clinicians to establish the Pancreatic Cancer Detection Consortium (PCDC) to conduct research to improve the detection of early stage pancreatic ductal adenocarcinoma (PDAC) and characterization of its precursor lesions.


Statins, Pancreatitis and Pancreatic Cancer Findings Lead to a Clinical Trial


- Simvastatin is associated with reduced risk of acute pancreatitis: findings from a regional integrated healthcare system. Wu BU, Pandol SJ, Liu IL. Gut 2015;64:133-138.
- The association of statin use after cancer diagnosis with survival in pancreatic cancer patients: a SEER-medicare analysis. Jeon CY, Pandol SJ, Wu B, Cook-Wiens G, Gottlieb RA, Merz CN, Merz NB, Goodman MT. PLoS One 2015;10:e0121783.
- Impact of Statin Use on Survival in Patients Undergoing Resection for Early-Stage Pancreatic Cancer. Wu BU, Chang J, Jeon CY, Pandol SJ, Huang B, Ngor EW, Difronzo AL, Cooper RM. *Am J Gastroenterol* 2015;110:1233-1239.


How we study pancreatic cancer and develop treatments and early diagnosis methods

Using animal models of pancreatic cancer









No Effective Treatment for Pancreatic Cancer


- Abraxane: Drug of choice used with Gemcitabine to slow tumor growth.
- Abraxane / Gemcitabine increases survival by only 1.8 months.

Avenzoar Pharmaceuticals

Why Failure of Drugs to Treat Pancreatic Cancer?

- High metastasis level
- Pancreatic cancer cell **resistance** to treatments

Avenzoar Pharmaceuticals



Solution: *Metavert*™ Drug Treatment


- Metavert™ is a drug that has shown significant slower tumor growth with much less toxicity in pre-clinical trials.
- Metavert™ prevents metastasis and reduces resistance to chemo/radio therapy.
- Metavert™ can be combined with the treatments available because it affects a unique target.
- *Metavert™ does not* affect normal cells compared to standard chemotherapy drugs.


Avenzoar Pharmaceuticals

Metavert™


Pre-Clinical Trial Results

Avenzoar Pharmaceuticals





Metavert™ Prevents Cancer Cell Metastasis Control Metavert Metavert Metavert (150nM) (300nM) (600nM) Avenzoar Pharmaceuticals



The road to defeating this disease

- Team efforts for scientific skills and leadership in setting a sustained effort.
- Public (government and non-profits) and private leadership in identifying and supporting the team efforts.
- Focus on development of early diagnostic tests, prevention strategies and new treatments.